SLS Berita Valas

SELLAS Says FDA Grants Rare Pediatric Disease Designation For SLS009 To Treat Pediatric ALL

Biopharmaceutical company SELLAS Life Sciences Group, Inc. (SLS) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to SLS009, a highly selective CDK9 inhibitor, for the treatment of pediatric acute lymphoblastic leukemia (ALL).

RTTNews | 414 days ago

SELLAS Life Sciences Reports Positive Topline Data In Lymphoma Cohort From SLS009 Phase 1 Trial

SELLAS Life Sciences Group, Inc. (SLS) announced Thursday positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from the Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009).

RTTNews | 692 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.17197	GBPUSD	1.35676	AUDUSD	0.6552
USDJPY	147.213	USDCAD	1.37599	USDCHF	0.80272